참고문헌
- Ashworth A (2008). A synthetic lethal therapeutic approach: Poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol, 26, 3785-90. https://doi.org/10.1200/JCO.2008.16.0812
- Arslan UY, Oksuzoglu B, Aksoy S, et al (2011). Breast cancer subtypes and outcomes of central nervous system metastases. Breast, 20, 562-7. https://doi.org/10.1016/j.breast.2011.07.017
- Bendell JC, Domchek SM, Burstein HJ, et al (2003). Central nervous system metastases in women receive trastuzumabbased therapy for metastatic breast carcinoma. Cancer, 97, 2972-7. https://doi.org/10.1002/cncr.11436
- Boogerd W (1996). Central nervous system metastasis in breast cancer. Radiother Oncol, 40, 5-22. https://doi.org/10.1016/0167-8140(96)01766-5
- Brodowicz T, Kostler WJ, Moslinger R, et al (2000). Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast, 9, 338-42. https://doi.org/10.1054/brst.2000.0170
- Byrski T, Huzarski T, Dent R, et al (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, 115, 359-63. https://doi.org/10.1007/s10549-008-0128-9
- Cancer staging manual AJCC (2010) Seventh Edition, Springer, Chicago.
- Carey LA, Ewend MG, Metzger R, et al (2004). Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat, 88, 273-80. https://doi.org/10.1007/s10549-004-0999-3
- Carmichael J, Possinger K, Philip P, et al (1995). Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol, 13, 2731-6.
- DiStefano A, Yong YY, Hortobagyi GN, Blumenschein GR (1979). The natural history of breast cancer patients with brain metastases. Cancer, 44, 1913-8. https://doi.org/10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D
- Doroshow J, Tetef M, Margolin K, et al (2000). Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): a california cancer consortium/loyola Univ. Chicago Trial (Abstract). Proc Am Soc Clin Oncol, 19, 609.
- Eichler AF, Kuter I, Ryan P, et al (2008). Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer, 112, 2359-67. https://doi.org/10.1002/cncr.23468
- Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer:experience from a large study with long-term followup. Histopathology, 19, 403-10. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
- Forastiere AA, Hakes TB, Wittes JT, Wittes RE (1982). Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol, 5, 243-7. https://doi.org/10.1097/00000421-198206000-00001
- Fitzgibbons PL, Page DL, Weaver D, et al (2000). Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med, 124, 966-78.
- Gabos Z, Sinha R, Hanson J, et al (2006). Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol, 24, 5638-63.
- Galvez CA, Calmarini F, Curie M (2000). Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer (Abstract). Breast Cancer Res Treat, 64, 81.
- Gorbunova VA, Bychkov MB, Naskhletashvili DR, et al (2010). Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases. J Clin Oncol, 28, 15. https://doi.org/10.1200/JCO.2008.20.9288
- Heinemann V (2002). Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer, 3, 24-9. https://doi.org/10.3816/CBC.2002.s.006
- Heinemann V, Stemmler HJ, Wohlrab A, et al (2006). High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol, 57, 640-6. https://doi.org/10.1007/s00280-005-0093-5
- Husain A, He G, Venkatraman ES, Spriggs DR (1998). BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res, 58, 1120-3.
- Kim H-J, Im S-A, Keam B, et al (2012). Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol, 106, 303-13. https://doi.org/10.1007/s11060-011-0664-8
- Kirsch DG, Ledezma CJ, Mathews CS, et al (2005). Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol, 23, 2114-6. https://doi.org/10.1200/JCO.2005.05.249
- Kolaric K, Roth A (1983). Phase II clinical trial of cisdichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol, 11, 108-12. https://doi.org/10.1007/BF00254257
- Lee SS, Ahn J-H, Kim MK, et al (2008). Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat, 111, 523-30. https://doi.org/10.1007/s10549-007-9806-2
- Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW (2007). The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest, 117, 1370-80. https://doi.org/10.1172/JCI30866
- Maki DD, Grossman RI (2000). Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neuroradiol, 21, 1064-6.
- Miller AB, Hoogstraten B, Staquet M, Winkler A (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
- Nam BH, Kim SY, Han HS, et al (2008). Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res, 10, 20.
- Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000). Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol, 18, 2245-9.
- Niwinska A, Murawska M, Pogoda K (2010). Breast cancer brain metastasis: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT). Ann Oncol, 21, 942-8. https://doi.org/10.1093/annonc/mdp407
- Niwinska A, Murawska M, Pogoda K (2010). Breast cancer subtypes and response to systemic treatment after wholebrain radiotherapy in patients with brain metastases. Cancer, 116, 4238-47. https://doi.org/10.1002/cncr.25391
- Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol, 5, 649-55. https://doi.org/10.1097/00000421-198212000-00014
- Ostrow S, Egorin M, Aisner J, Bchur N, Wiernik PH (1980). High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials, 3, 23-7.
- Park B-B, Uhm JE, Cho EY, et al (2009). Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes? Cancer Chemother Pharmacol, 63, 627-33. https://doi.org/10.1007/s00280-008-0779-6
- Ryberg M, Nielsen D, Osterlind K, et al (2005). Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat, 91, 217-25. https://doi.org/10.1007/s10549-005-0323-x
- Samaan NA, Buzdar AU, Aldinger KA, et al (1981). Estrogen receptor: a prognostic factor in breast cancer. Cancer (Phila), 47, 554-60. https://doi.org/10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W
- Shen SX, Weaver Z, Xu X, et al (1998). A targeted disruption of the murine brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene, 17, 3115-24. https://doi.org/10.1038/sj.onc.1202243
- Sledge GW Jr. Loehrer PJ Sr. Roth BJ, Einhorn LH (1988). Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol, 6, 1811-4.
- Somali I, Alacacioglu A, Tarhan MO, et al (2009). Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy, 55, 155-60. https://doi.org/10.1159/000214143
- Spielmann M, Llombart- Cussac A, Kalla S, et al (2001). Singleagent gemcitabine is active in previously treated metastatic breast cancer. Oncology, 60, 303-7. https://doi.org/10.1159/000058524
- Tsukada Y, Fouad A, Pickren JW, Lane WW (1983). Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer (Phila), 52, 2349-54. https://doi.org/10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B
- Uhm JE, Park YH, Yi SY, et al (2009). Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer, 124, 1457-62. https://doi.org/10.1002/ijc.24090
- Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ (2012). Molecular insights on basal-like breast cancer. Breast Cancer Res Treat, 134, 21-30. https://doi.org/10.1007/s10549-011-1934-z
- Valerio M, Cicero G, Armata M, et al (2001). Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol, 20, 1953.
- World Health Organization: WHO handbook for reporting results of cancer treatment (1979) WHO Offset Publication, No. 48, Geneva, Switzerland.
피인용 문헌
- Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients vol.17, pp.4, 2014, https://doi.org/10.4048/jbc.2014.17.4.339
- Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation vol.12, pp.4, 2015, https://doi.org/10.1021/mp5008629
- Brain Metastases from Solid Tumors: an Institutional Study from South India vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5401
- Protective Role of Selenium and High Dose Vitamin E against Cisplatin - Induced Nephrotoxicty in Rats vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6877
- Incidence of Cisplatin-Induced Nephrotoxicity and Associated Factors among Cancer Patients in Indonesia vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1117
- A New Tool to Predict Survival after Radiosurgery Alone for Newly Diagnosed Cerebral Metastases vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2967
- )-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549) vol.89, pp.3, 2016, https://doi.org/10.1111/cbdd.12845
- A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer vol.7, pp.4, 2017, https://doi.org/10.1051/bmdcn/2017070423
- Leptomeningeal Metastases vol.19, pp.1, 2018, https://doi.org/10.1007/s11864-018-0518-0
- Metastatic and triple-negative breast cancer: challenges and treatment options vol.8, pp.5, 2018, https://doi.org/10.1007/s13346-018-0551-3